Openbookopenbook
Equity
VAL
+0.0 · +0.00%
GBX · LSE

ValiRx plc(VAL) Stock Analysis | Healthcare

GBX --+0.00%
Reward30Low
Risk44Moderate
75%Data
Revenue down 37% YoY
Earnings Deterioration
Market Cap:1.85M
ⓘ
Reward Rating
30
Low
Reward Assessment
75% data coverage
Bottom 1% of stocksView factors
ⓘ
Risk Rating
44
Moderate
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on VAL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is ValiRx plc?

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.

AI Brief Pro

The brief on ValiRx plc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is ValiRx plc?

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 1.85M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (30)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

BSFANano Cap / 2M market cap
BSF Enterprise Plc
Compare
FUMNano Cap / 1.6M market cap
Futura Medical
Compare
ROQNano Cap / 1.6M market cap
Roquefort Investments PLC
Compare
All Healthcare stocks →
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap1.85M
P/E RatioN/A
Dividend YieldN/A
Beta-0.61
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.